
Anna J Zaczek

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7890649/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Breast cancer circulating tumor cells with mesenchymal features—an unreachable target?. Cellular and Molecular Life Sciences, 2022, 79, 81.	2.4	12
2	Higher platelet counts correlate to tumour progression and can be induced by intratumoural stroma in non-metastatic breast carcinomas. British Journal of Cancer, 2022, 126, 464-471.	2.9	5
3	Chimeric virus-like particles presenting tumour-associated MUC1 epitope result in high titers of specific IgG antibodies in the presence of squalene oil-in-water adjuvant: towards safe cancer immunotherapy. Journal of Nanobiotechnology, 2022, 20, 160.	4.2	9
4	ERα36-High Cancer-Associated Fibroblasts as an Unfavorable Factor in Triple-Negative Breast Cancer. Cancers, 2022, 14, 2005.	1.7	1
5	Alpha-smooth muscle actin-positive cancer-associated fibroblasts secreting osteopontin promote growth of luminal breast cancer. Cellular and Molecular Biology Letters, 2022, 27, .	2.7	24
6	Reduced expression of innate immunity-related genes in lymph node metastases of luminal breast cancer patients. Scientific Reports, 2021, 11, 5097.	1.6	11
7	Cytocompatibility of stabilized black phosphorus nanosheets tailored by directly conjugated polymeric micelles for human breast cancer therapy. Scientific Reports, 2021, 11, 9304.	1.6	14
8	imPlatelet classifier: imageâ€converted RNA biomarker profiles enable bloodâ€based cancer diagnostics. Molecular Oncology, 2021, 15, 2688-2701.	2.1	16
9	Low Tumor-to-Stroma Ratio Reflects Protective Role of Stroma against Prostate Cancer Progression. Journal of Personalized Medicine, 2021, 11, 1088.	1.1	3
10	Diagnostic Accuracy of Liquid Biopsy in Endometrial Cancer. Cancers, 2021, 13, 5731.	1.7	13
11	microRNA Expression Profile in Single Hormone Receptor-Positive Breast Cancers Is Mainly Dependent on HER2 Status—A Pilot Study. Diagnostics, 2020, 10, 617.	1.3	7
12	Circulating Tumor Cells in Early and Advanced Breast Cancer; Biology and Prognostic Value. International Journal of Molecular Sciences, 2020, 21, 1671.	1.8	34
13	Liquid biopsy for minimally invasive heart transplant monitoring: a pilot study. Journal of Clinical Pathology, 2020, 73, 507-510.	1.0	4
14	Low Numbers of Vascular Vessels Correlate to Progression in Hormone-NaÃ⁻ve Prostate Carcinomas Undergoing Radical Prostatectomy. Cancers, 2019, 11, 1356.	1.7	7
15	Clinical and Biological Significance of ESR1 Gene Alteration and Estrogen Receptors Isoforms Expression in Breast Cancer Patients. International Journal of Molecular Sciences, 2019, 20, 1881.	1.8	8
16	Sensitive detection of caspase-3 enzymatic activities and inhibitor screening by mass spectrometry with dual maleimide labelling quantitation. Analyst, The, 2019, 144, 6751-6759.	1.7	6
17	The Prognostic Significance of Eukaryotic Translation Initiation Factors (eIFs) in Endometrial Cancer. International Journal of Molecular Sciences, 2019, 20, 6169.	1.8	9
18	NF-kappa B Signaling-Related Signatures Are Connected with the Mesenchymal Phenotype of Circulating Tumor Cells in Non-Metastatic Breast Cancer. Cancers, 2019, 11, 1961.	1.7	18

Anna J Zaczek

#	Article	IF	CITATIONS
19	Spectrum of Epithelial-Mesenchymal Transition Phenotypes in Circulating Tumour Cells from Early Breast Cancer Patients. Cancers, 2019, 11, 59.	1.7	47
20	Sensitive Detection of Single-Cell Secreted H ₂ O ₂ by Integrating a Microfluidic Droplet Sensor and Au Nanoclusters. Analytical Chemistry, 2018, 90, 4478-4484.	3.2	77
21	Aggressive Phenotype of Cells Disseminated via Hematogenous and Lymphatic Route in Breast Cancer Patients. Translational Oncology, 2018, 11, 722-731.	1.7	19
22	MiR-192 and miR-662 enhance chemoresistance and invasiveness of squamous cell lung carcinoma. Lung Cancer, 2018, 118, 111-118.	0.9	38
23	RSK1 promotes murine breast cancer growth and metastasis. Folia Histochemica Et Cytobiologica, 2018, 56, 11-20.	0.6	5
24	The Landscape of Circulating Tumor Cell Research in the Context of Epithelial-Mesenchymal Transition. Pathobiology, 2017, 84, 264-283.	1.9	16
25	Fibroblast growth factor signalling induces loss of progesterone receptor in breast cancer cells. Oncotarget, 2016, 7, 86011-86025.	0.8	18
26	Keratin 7 expression in lymph node metastases but not in the primary tumour correlates with distant metastases and poor prognosis in colon carcinoma. Polish Journal of Pathology, 2016, 3, 228-234.	0.1	14
27	HOTAIR in Relation to Epithelial-Mesenchymal Transition and Cancer Stem Cells in Molecular Subtypes of Endometrial Cancer. International Journal of Biological Markers, 2016, 31, 245-251.	0.7	21
28	Interactions between FGFR2 and RSK2—implications for breast cancer prognosis. Tumor Biology, 2016, 37, 13721-13731.	0.8	11
29	Endometrial cancer in patients after previous neoplasmatic disease – clinical and molecular aspects Ginekologia Polska, 2016, 87, 88-93.	0.3	Ο
30	CD99 correlates with low cyclin D1, high topoisomerase 2ï 1 status and triple negative molecular phenotype but is prognostically irrelevant in breast carcinoma. Polish Journal of Pathology, 2015, 3, 269-275.	0.1	4
31	Stromal expression of ALDH1 in human breast carcinomas indicates reduced tumor progression. Oncotarget, 2015, 6, 26789-26803.	0.8	18
32	Immunohistochemical characterisation of molecular subtypes in endometrial cancer. International Journal of Clinical and Experimental Medicine, 2015, 8, 21981-90.	1.3	3
33	A multimarker qPCR platform for the characterisation of endometrial cancer. Oncology Reports, 2014, 31, 1003-1013.	1.2	6
34	HER2â€Positive Endometrial Cancer Subtype Carries Poor Prognosis. Clinical and Translational Science, 2014, 7, 482-488.	1.5	26
35	Are bilateral breast cancers and breast cancers coexisting with ovarian cancer different from solitary tumors? A pairâ€matched immunohistochemical analysis aimed at intrinsic tumor phenotype. Pathology International, 2014, 64, 508-517.	0.6	3
36	Phosphorylation of RSK2 at Tyr529 by FGFR2-p38 enhances human mammary epithelial cells migration. Biochimica Et Biophysica Acta - Molecular Cell Research, 2014, 1843, 2461-2470.	1.9	20

Anna J Zaczek

#	Article	IF	CITATIONS
37	Tumor Heterogeneity at Protein Level as an Independent Prognostic Factor in Endometrial Cancer. Translational Oncology, 2014, 7, 613-619.	1.7	28
38	Mesenchymal Phenotype of CTC-Enriched Blood Fraction and Lymph Node Metastasis Formation Potential. PLoS ONE, 2014, 9, e93901.	1.1	43
39	Are synchronous and metachronous bilateral breast cancers different? An immunohistochemical analysis aimed at intrinsic tumor phenotype. International Journal of Clinical and Experimental Pathology, 2014, 7, 353-63.	0.5	9
40	Epithelial-mesenchymal transition markers in lymph node metastases and primary breast tumors - relation to dissemination and proliferation. American Journal of Translational Research (discontinued), 2014, 6, 793-808.	0.0	20
41	Are bilateral breast cancers different from breast cancers coexisting with ovarian cancer? An immunohistochemical analysis aimed at intrinsic tumor phenotype. Breast, 2013, 22, 425-430.	0.9	1
42	Heterogeneity of Mesenchymal Markers Expression—Molecular Profiles of Cancer Cells Disseminated by Lymphatic and Hematogenous Routes in Breast Cancer. Cancers, 2013, 5, 1485-1503.	1.7	8
43	Prognostic Significance of ESR1 Amplification and ESR1 Pvull, CYP2C19*2, UGT2B15*2 Polymorphisms in Breast Cancer Patients. PLoS ONE, 2013, 8, e72219.	1.1	20
44	Epithelial-mesenchymal transition and cancer stem cells in endometrial cancer. Anticancer Research, 2013, 33, 5461-9.	0.5	14
45	Prognostic Significance of <i>TOP2A</i> Gene Dosage in HER-2-Negative Breast Cancer. Oncologist, 2012, 17, 1246-1255.	1.9	22
46	CD73 Expression as a Potential Marker of Good Prognosis in Breast Carcinoma. Applied Immunohistochemistry and Molecular Morphology, 2012, 20, 103-107.	0.6	68
47	Deregulation of RAD21 and RUNX1 expression in endometrial cancer. Oncology Letters, 2012, 4, 727-732.	0.8	26
48	Epithelial-Mesenchymal Transition: A Hallmark in Metastasis Formation Linking Circulating Tumor Cells and Cancer Stem Cells. Pathobiology, 2012, 79, 195-208.	1.9	168
49	Expression of epithelial to mesenchymal transition-related markers in lymph node metastases as a surrogate for primary tumor metastatic potential in breast cancer. Journal of Translational Medicine, 2012, 10, 226.	1.8	41
50	Prognostic Value of TOP2A Gene Amplification and Chromosome 17 Polysomy in Early Breast Cancer. Pathology and Oncology Research, 2012, 18, 885-894.	0.9	21
51	Clinical evaluation of developed PCR-based method with hydrolysis probes for TOP2A copy number evaluation in breast cancer samples. Clinical Biochemistry, 2010, 43, 891-898.	0.8	10
52	Pharmacogenetics in breast cancer hormone therapy. Wspolczesna Onkologia, 2010, 4, 242-247.	0.7	0
53	Gene copy numbers of HER family in breast cancer. Journal of Cancer Research and Clinical Oncology, 2007, 134, 271-279.	1.2	22
54	(CA)n Microsatellite polymorphism of ERBB-1 in breast cancer. European Journal of Cancer, 2006, 42, 1698-1701.	1.3	2

#	Article	IF	CITATIONS
55	p53 Gene status in relation to ex vivo chemosensitivity of non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology, 2002, 128, 141-147.	1.2	28